Tarsus Pharmaceuticals to Attend Major Investor Conferences
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), located in Irvine, California, is gearing up to engage with investors by participating in a series of prominent conferences. These events provide Tarsus an excellent platform to showcase their innovative approach and advancements in the health care sector.
Upcoming Conferences
Management has announced participation in three significant conferences that promise to facilitate important discussions around the company's ongoing projects and visions for the future.
William Blair 45th Annual Growth Stock Conference
This event is set to take place on a Tuesday morning, giving Tarsus an opportunity to present at 6:00 a.m. PT / 8:00 a.m. CT. It is a notable gathering where investors can gain insights into the growth strategies of various companies, including Tarsus.
Jefferies Global Healthcare Conference
Following the William Blair event, Tarsus will be featured at the Jefferies Global Healthcare Conference on Wednesday at 12:45 p.m. PT / 3:45 p.m. ET. This gathering is pivotal in the healthcare domain, allowing participants to delve deeper into the industry trends and individual company performances.
Goldman Sachs 46th Annual Global Healthcare Conference
Next in line is the Goldman Sachs conference happening on a Monday at 10:20 a.m. PT / 1:20 p.m. ET. This conference often attracts a wide array of healthcare investors and innovators, setting the stage for Tarsus to engage with key stakeholders in the sector.
Access to Live Webcasts
Tarsus Pharmaceuticals encourages interested stakeholders to access live webcasts of these presentations. The links and additional details will be available in the events section of the company's website. In addition to the live sessions, recorded replays will also be made accessible within 48 hours, allowing for a broader audience to catch up on the discussions.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is dedicated to leveraging scientific expertise and cutting-edge technology to transform patient care, initially focusing on eye care. The company’s pipeline is innovative, targeting several conditions that currently lack effective treatments across diverse therapy areas. Their FDA-approved product, XDEMVY (lotilaner ophthalmic solution) 0.25%, specifically addresses Demodex blepharitis.
Additionally, Tarsus is working on TP-04, aimed at treating ocular rosacea, and TP-05, an oral medication designed for the prevention of Lyme disease, reflecting the company’s commitment to addressing significant healthcare needs.
Contact Information
For media inquiries, please reach out to:
Adrienne Kemp
Sr. Director, Corporate Communications
Phone: (949) 922-0801
Email: AKemp@tarsusrx.com
For investor relations, contact:
David Nakasone
Head of Investor Relations
Phone: (949) 620-3223
Email: DNakasone@tarsusrx.com
Frequently Asked Questions
What is Tarsus Pharmaceuticals known for?
Tarsus Pharmaceuticals is recognized for its innovative treatments in healthcare, especially focusing on eye care and infectious disease prevention.
Where is Tarsus Pharmaceuticals located?
The company is based in Irvine, California, where it conducts its primary operations.
What kind of conferences is Tarsus participating in?
Tarsus is attending investor conferences that allow them to present their advancements and future plans to potential investors.
How can investors access the conference details?
Live webcasts and additional conference details will be available in the events section of the Tarsus website.
What is XDEMVY?
XDEMVY is an FDA-approved treatment specifically developed for Demodex blepharitis and represents part of Tarsus' pipeline aimed at addressing high unmet medical needs.
